Changmao Biochemical Engineering Bilan de santé

Santé financière contrôle des critères 1/6

Changmao Biochemical Engineering possède un total de capitaux propres de CN¥633.0M et une dette totale de CN¥532.7M, ce qui porte son ratio d'endettement à 84.2%. Son actif total et son passif total sont CN¥1.3B et de CN¥635.7M.

Informations clés

84.2%

Ratio d'endettement

CN¥532.73m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	CN¥71.97m
Fonds propres	CN¥633.01m
Total du passif	CN¥635.71m
Total des actifs	CN¥1.27b

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Further Upside For Changmao Biochemical Engineering Company Limited (HKG:954) Shares Could Introduce Price Risks After 25% Bounce

Sep 23

Investors Will Want Changmao Biochemical Engineering's (HKG:954) Growth In ROCE To Persist

Aug 02

Returns On Capital At Changmao Biochemical Engineering (HKG:954) Have Stalled

Nov 18

We Believe Changmao Biochemical Engineering's (HKG:954) Earnings Are A Poor Guide For Its Profitability

Apr 28

Changmao Biochemical Engineering (HKG:954) Will Be Looking To Turn Around Its Returns

Aug 03

Changmao Biochemical Engineering (HKG:954) May Have Issues Allocating Its Capital

May 04

Tread With Caution Around Changmao Biochemical Engineering Company Limited's (HKG:954) 8.8% Dividend Yield

Feb 23

Will Changmao Biochemical Engineering (HKG:954) Multiply In Value Going Forward?

Jan 26

A Quick Analysis On Changmao Biochemical Engineering's (HKG:954) CEO Salary

Dec 02

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 954 ( CN¥318.3M ) ne couvrent pas ses passifs à court terme ( CN¥367.5M ).

Passif à long terme: Les actifs à court terme de 954 ( CN¥318.3M ) dépassent ses passifs à long terme ( CN¥268.2M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de 954 ( 72.8% ) est considéré comme élevé.

Réduire la dette: Le ratio d'endettement de 954 est passé de 0.08% à 84.2% au cours des 5 dernières années.

Couverture de la dette: Le flux de trésorerie opérationnel de 954 est négatif, par conséquent la dette n'est pas bien couverte.

Couverture des intérêts: Données insuffisantes pour déterminer si les paiements d'intérêts de 954 sur sa dette sont bien couverts par l'EBIT.

Changmao Biochemical Engineering Bilan de santé

Santé financière contrôle des critères 1/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Non-Executive Director recently bought HK$141k worth of stock

Further Upside For Changmao Biochemical Engineering Company Limited (HKG:954) Shares Could Introduce Price Risks After 25% Bounce

First half 2024 earnings released: CN¥0.035 loss per share (vs CN¥0.008 profit in 1H 2023)

Changmao Biochemical Engineering Company Limited to Report First Half, 2024 Results on Aug 16, 2024

Chairman & Compliance Officer recently bought HK$132k worth of stock

Chairman & Compliance Officer recently bought HK$836k worth of stock

Chairman & Compliance Officer recently bought HK$164k worth of stock

Changmao Biochemical Engineering Company Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings released: CN¥0.16 loss per share (vs CN¥0.15 profit in FY 2022)

New minor risk - Financial data availability

Changmao Biochemical Engineering Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Chairman & Compliance Officer recently bought HK$59k worth of stock

Chairman & Compliance Officer recently bought HK$231k worth of stock

Chairman & Compliance Officer recently bought HK$54k worth of stock

Chairman & Compliance Officer recently bought HK$327k worth of stock

Chairman & Compliance Officer recently bought HK$277k worth of stock

New major risk - Financial position

First half 2023 earnings released: EPS: CN¥0.008 (vs CN¥0.077 in 1H 2022)

Changmao Biochemical Engineering Company Limited to Report First Half, 2023 Results on Aug 18, 2023

Investors Will Want Changmao Biochemical Engineering's (HKG:954) Growth In ROCE To Persist

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Changmao Biochemical Engineering Company Limited approves Final Dividend for the Year Ended 31 December 2022, Payable on 18 July 2023

Upcoming dividend of CN¥0.077 per share at 8.4% yield

Full year 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.11 in FY 2021)

Returns On Capital At Changmao Biochemical Engineering (HKG:954) Have Stalled

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.077 (vs CN¥0 in 1H 2021)

Changmao Biochemical Engineering Company Limited Announces Appointment of Ms. Cheng Mun Wah as Independent Non-Executive Director and Chairman of Audit Committee, and Member of Remuneration Committee and Nomination Committee

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0 in 1H 2021)

Changmao Biochemical Engineering Company Limited to Report First Half, 2022 Results on Aug 18, 2022

Changmao Biochemical Engineering Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Changmao Biochemical Engineering Company Limited Appoints Cheng Mun Wah as Independent Non-Executive Director and Chairman of Audit Committee and Member of Remuneration Committee and Nomination Committee

Changmao Biochemical Engineering Company Limited Approves Board Resignations, Effective 18 June 2022

We Believe Changmao Biochemical Engineering's (HKG:954) Earnings Are A Poor Guide For Its Profitability

Less than half of directors are independent

Changmao Biochemical Engineering Company Limited Omits Final Dividend for the Year Ended 31 December 2021

Full year 2021 earnings released

Changmao Biochemical Engineering (HKG:954) Will Be Looking To Turn Around Its Returns

Upcoming dividend of CN¥0.02 per share

Changmao Biochemical Engineering (HKG:954) May Have Issues Allocating Its Capital

Full year 2020 earnings released: EPS CN¥0.032 (vs CN¥0.11 in FY 2019)

Full year 2020 earnings released

Changmao Biochemical Engineering Company Limited Provides Earnings Guidance for the Year Ended 31 December 2020

Changmao Biochemical Engineering Company Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Tread With Caution Around Changmao Biochemical Engineering Company Limited's (HKG:954) 8.8% Dividend Yield

Will Changmao Biochemical Engineering (HKG:954) Multiply In Value Going Forward?

New 90-day high: HK$0.65

A Quick Analysis On Changmao Biochemical Engineering's (HKG:954) CEO Salary

New 90-day low: HK$0.56

First half earnings released

New 90-day low - HK$0.59

First half earnings released

Changmao Biochemical Engineering Company Limited to Report First Half, 2020 Results on Aug 28, 2020

New 90-day low - HK$0.60

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines